1. Introduction {#sec1-molecules-21-00008}
===============

2′,3′,5′-Tri-*O*-acetyl-*N*~6~-(3-hydroxyphenyl) adenosine (also known as WS070117) is a new adenosine analog anti-hyperlipidemic drug candidate currently in many preclinical studies \[[@B1-molecules-21-00008],[@B2-molecules-21-00008],[@B3-molecules-21-00008],[@B4-molecules-21-00008],[@B5-molecules-21-00008]\]. Guo and coworkers have investigated and elucidated the *in vivo* metabolites of WS070117 in rat urine after oral administration of WS070117 by HPLC-DAD, ESI-MS and Off-Line Microprobe NMR \[[@B6-molecules-21-00008]\]. In the study, seven metabolites of WS070117 were observed in the HPLC trace (the metabolites are ranked **M2**--**M8** according to the retention time; [Figure 1](#molecules-21-00008-f001){ref-type="fig"}). The structure elucidation results unambiguously revealed that there are two phase I metabolites, including a deacetylation product of WS070117 (**M8**) and an adenine derivative formed by the loss of ribofuranose (**M7**). In addition, there are five phase II metabolites: **M6** is the oxidation product of **M7** at C-8; **M2** and **M4** are the glycosylation products of **M7** and **M8** on the phenolic hydroxyl groups, respectively; **M3** and **M5** are the sulfonylation products of **M6** and **M8**, respectively. Herein, the synthesis of the above metabolites was carried out to provide metabolites material standards for preclinical pharmacokinetic studies.

2. Results and Discussion {#sec2-molecules-21-00008}
=========================

The metabolite **M8** was prepared in quantitative yield by the hydrolysis of the acetyl groups in WS070117 with NaOH \[[@B7-molecules-21-00008]\] ([Scheme 1](#molecules-21-00008-f002){ref-type="scheme"}). Treatment of WS070117 with chlorosulfonic acid \[[@B8-molecules-21-00008]\] afforded the corresponding sulphonate **1**, which was converted to the desired product **M5** by subsequent deacetylation with Na~2~CO~3~. Direct hydrolysis of the glycosidic bond in WS070117 with concentrated hydrochloric acid and 95% ethanol solution at reflux smoothly afforded **M7**.

We initially attempted to synthesize **M6** by bromination and hydrolysis reactions at C-8 of **M7** \[[@B9-molecules-21-00008]\], but liquid bromine and NaH did not afford the needed C8-brominated adenine. Then 4,5-diamino-6-chloropyrimidine **2** and *N*,*N′*-carbonyldiimidazole (CDI) were employed to synthesize 8-hydroxy-6-chloroadenine (**3**) \[[@B10-molecules-21-00008]\], which could be ammoniated at C-6 to prepare **M6** ([Scheme 2](#molecules-21-00008-f003){ref-type="scheme"}). The amination was catalyzed by hydrochloric acid to afford the desired product in 70% yield at 120 °C in a microwave reactor. Subsequent sulfonylation of **M6** with sulfur trioxide-pyridine complex gave the target metabolite **M3**.

![The structures of the WS070117 metabolites in rat urine.](molecules-21-00008-g001){#molecules-21-00008-f001}

![The synthesis of **M5**, **M7** and **M8**.](molecules-21-00008-g002){#molecules-21-00008-f002}

![The synthesis of **M3** and **M6**.](molecules-21-00008-g003){#molecules-21-00008-f003}

Initially, the glycosylation reaction with tetra-*O*-acetyl-β-[d]{.smallcaps}-glucopyranuronic acid methyl ester as the donor and WS070117 as the receptor was catalyzed by SnCl~4~ to synthesize **M4**, but the yield of the desired product was poor, with the formation of a complex mixture of by-products. The Koenigs--Knorr glycosylation reaction with acetobromo-α-[d]{.smallcaps}-glucuronic acid methyl ester as the donor was then employed, but Ag~2~O failed to catalyze the reaction even at two equivalents, which may be due to its complexation with the nitrogen-atoms. Afterwards the Schmitt glycosylation reaction was tried with trichloroacetimidate as donor ([Scheme 3](#molecules-21-00008-f004){ref-type="scheme"}). A series of conditions for selective anomeric deacetylation of **4** were investigated, including benzylamine/DMF \[[@B11-molecules-21-00008]\], FeCl~3~·6H~2~O/CH~3~CN \[[@B12-molecules-21-00008]\] and Nd(OTf)~3~/CH~3~OH \[[@B13-molecules-21-00008]\]. The results showed that Nd(OTf)~3~/CH~3~OH gave a cleaner reaction in quantitative yield and the product could be used directly in the next step without purification. Under the catalysis of BF~3~·Et~2~O, trichloroacetimidate **6** reacted smoothly with WS070117 to give the desired β-glucoside **7** due the neighboring group participation effect. After deacetylation with Cs~2~CO~3~, **M4** was obtained in 83.3% yield. However, the glycosylation reaction of M7 under the same conditions only afforded the desired product **M2** with a 25% conversion because of the poor solubility of the raw material in dichloromethane. An alternate route such as selective hydrolysis of the N-glycoside bond of **M4** with aqueous hydrochloric acid solution afforded **M2** in moderate yield.

![The synthesis of **M4** and **M2**.](molecules-21-00008-g004){#molecules-21-00008-f004}

3. Materials and Methods {#sec3-molecules-21-00008}
========================

3.1. General Information {#sec3dot1-molecules-21-00008}
------------------------

WS070117 was prepared in our laboratory in 98% purity. Unless otherwise indicated, all commercial reagents and solvents were used without additional purification. ^1^H-NMR and ^13^C-NMR spectra were recorded on a Mercury-300M (Varian, Salt Lake City, UT, USA,) or Bruker 400M (Varian) spectrometer. Chemical shifts (in ppm) were referenced to tetramethylsilane (δ = 0) in deuterated solvent as internal standard. HPLC-mass spectra (ESI) were recorded on an Acquity UPLC-MS system (Waters, Milford, MA, UK). Optical rotations were recorded on p-2000 polarimeter (Jasco, Tokyo, Japan) at 20 °C in 589 nm.

3.2. Synthesis of N~6~-(3-Hydroxyphenyl) Adenosine *(**M8**)* {#sec3dot2-molecules-21-00008}
-------------------------------------------------------------

NaOH (2.1 g, 52.5 mmol) was added to a stirred suspension of WS070117 (8.0 g, 16.5 mmol) in H~2~O (50 mL), and the mixture was stirred at room temperature for 2 h until the disappearance of the solid. The solution was cooled to 5 °C and the precipitated solid was filtered and washed with water to give **M8** (5.90 g, 99%) as a white solid, $\left\lbrack \mathsf{\alpha} \right\rbrack_{D}^{20}$ = −40.7 (*c* = 0.4, H~2~O), ESI/MS: 360.15 \[M + H\]^+^, ^1^H-NMR (300 MHz, methanol-*d*~4~, see [Supplementary Materials](#app1-molecules-21-00008){ref-type="app"}) δ 8.34 (d, *J* = 5.0 Hz, 2H), 7.27 (t, *J* = 2.1 Hz, 1H), 7.15--6.99 (m, 2H), 6.52 (dt, *J* = 7.5, 1.8 Hz, 1H), 6.00 (d, *J* = 6.3 Hz, 1H), 4.77 (dd, *J* = 6.3, 5.1 Hz, 1H), 4.34 (dd, *J* = 5.1, 2.6 Hz, 1H), 4.19 (q, *J* = 2.6 Hz, 1H), 3.90 (dd, *J* = 12.6, 2.6 Hz, 1H), 3.76 (dd, *J* = 12.5, 2.8 Hz, 1H). ^13^C-NMR (100 MHz, methanol-*d*~4~) δ 161.6, 156.5, 155.8, 152.5, 151.9, 144.8, 143.9, 133.1, 115.6, 114.4, 111.6, 93.9, 90.7, 78.1, 75.2, 66.0.

3.3. Synthesis of N~6~-(3-O-Sulfophenyl) Adenosine *(**M5**)* {#sec3dot3-molecules-21-00008}
-------------------------------------------------------------

Chlorosulfonic acid (300 μL, 4.6 mmol) was added dropwise (*carefully!*) into a stirred solution of WS070117 (130 mg, 0.27 mmol) in dry pyridine (3 mL) at 0 °C under N~2~. The solution was warmed to room temperature and stirred for 12 h. Na~2~CO~3~ (aq, 0.5 M, 20 mL) was then added to adjust the pH to 10. The reaction mixture was stirred for another 12 h at room temperature, and the solvent was removed *in vacuo* and the remaining solid was purified by Sephadex LH-20 chromatography eluting with water to give **M5** (78 mg, 66.3%) as a white solid, $\left\lbrack \mathsf{\alpha} \right\rbrack_{D}^{20}$ = −33.5 (*c* = 0.15, H~2~O), ESI/MS: 440.10 \[M + H\]^+^, ^1^H-NMR (300 MHz, D~2~O, see [Supplementary Materials](#app1-molecules-21-00008){ref-type="app"}) δ 8.28 (s, 1H), 8.21 (s, 1H), 7.50 (t, *J* = 3.8 Hz, 1H), 7.40 (t, *J* = 5.7 Hz, 2H), 7.10 (p, *J* = 7.7 Hz, 1H), 6.03 (dd, *J* = 5.9, 2.6 Hz, 1H), 4.76--4.67 (m, 1H), 4.41 (dd, *J* = 5.4, 3.7 Hz, 1H), 4.28 (dq, *J* = 6.2, 3.4 Hz, 1H), 3.93 (dd, *J* = 12.9, 2.94 Hz, 1H), 3.83 (dd, *J* = 12.9, 3.7 Hz, 1H). ^13^C-NMR (100 MHz, D~2~O) δ180.2, 152.0, 151.5, 148.4, 140.9, 138.6, 130.1, 120.1, 117.7, 115.4, 88.5, 85.8, 73.9, 70.7, 68.0, 61.5.

3.4. Synthesis of N~6~-(3-Hydroxyphenyl) Adenine *(**M7**)* {#sec3dot4-molecules-21-00008}
-----------------------------------------------------------

Concentrated hydrochloric acid (5 mL) was added into a stirred solution of WS070117 (4.85 g, 10 mmol) in 95% ethanol (100 mL). The reaction was refluxed for 1 h and then cooled to room temperature. The precipitated solid was filtered and washed with water to give **M7** (2.1 g, 92.5%) as a white solid, ESI/MS: 228.05 \[M + H\]^+^, ^1^H-NMR (300 MHz, DMSO-*d*~6~, see [Supplementary Materials](#app1-molecules-21-00008){ref-type="app"}) δ11.22 (s, 1H), 9.61 (brs, 1H), 8.74 (s, 1H), 8.70 (s, 1H), 7.42 (s, 1H), 7.31 (d, *J* = 10.4 Hz, 1H), 7.20 (t, *J* = 8.0 Hz, 1H), 6.62 (d, *J* = 8.0 Hz, 1H). ^13^C-NMR (100 MHz, DMSO-*d*~6~) δ 158.3, 150.0, 148.9, 148.8, 143.8, 139.1, 130.1, 113.3, 112.6, 112.6, 109.0.

3.5. Synthesis of 8-Hydroxy-N~6~-(3-hydroxy-phenyl) Adenine *(**M6**)* {#sec3dot5-molecules-21-00008}
----------------------------------------------------------------------

*N*,*N′*-Carbonyldiimidazole (CDI, 1.6 g, 10 mmol) was added into a stirred solution of 4,5-diamino-6-chloropyrimidine (**2**, 0.76 g, 5.23 mmol) in 1,4-dioxane. The reaction mixture was refluxed for 6 h and then cooled to room temperature. The precipitated solid was filtered and washed with water to give 8-hydroxy-6-chloroadenine (**3**, 700 mg). Concentrated hydrochloric acid (1 mL) was then added into a stirred solution of intermediate **3** (0.7 g, 4.12 mmol) and 3-aminophenol (0.7 g, 6.42 mmol) in ethanol (20 mL) in a sealed tube, which was irradiated in a microwave reactor at 120 °C for 4 h and then cooled to room temperature. The precipitating solid was filtered and washed with water to give **M6** (0.9g, 70%) as a white solid, ESI/MS: 244.07 \[M + H\]^+^, ^1^H-NMR (400 MHz, DMSO-*d*~6~, see [Supplementary Materials](#app1-molecules-21-00008){ref-type="app"}) δ 11.69 (s, 1H), 10.80 (s, 1H), 9.43 (s, 1H), 8.25 (s, 1H), 7.33 (s, 1H), 7.22--7.10 (m, 2H), 6.48 (d, *J* = 4.0 Hz, 1H). ^13^C-NMR (100 MHz, DMSO-*d*~6~) δ 158.2, 152.9, 149.5, 148.1, 142.5, 140.9, 129.9, 110.8, 110.2, 107.1, 106.3.

3.6. Synthesis of 8-Hydroxy-N~6~-(3-O-sulfophenyl) Adenine *(**M3**)* {#sec3dot6-molecules-21-00008}
---------------------------------------------------------------------

SO~3~·Pyr complex (9.54 g, 60 mmol) was added into a stirred solution of **M6** (2.27 g, 9.3 mmol) in pyridine (50 mL) and DMF (50 mL) at room temperature. After 24 h, acetone (200 mL) was added and the precipitated solid was filtered and washed with water to give **M3** (2.01 g, 67.2%) as a white solid, ^1^H-NMR (300 MHz, DMSO-*d*~6~) δ 8.84 (s), 8.20 (s, 1H), 7.61 (dd, *J* = 8.2, 2.3 Hz, 1H), 7.51 (dd, *J* = 2.3, 2.2 Hz, 1H), 7.18 (dd, *J* = 8.2 Hz, 1H), 6.77 (dd, *J* = 8.2, 2.2 Hz, 1H). ^13^C-NMR (100 MHz, DMSO-*d*~6~) δ 154.3, 153.5, 150.7, 149.4, 142.4, 141.2, 129.3, 114.5, 114.7, 111.4, 106.3.

3.7. Synthesis of Intermediate ***7*** {#sec3dot7-molecules-21-00008}
--------------------------------------

Nd(OTf)~3~ (0.95 g, 1.6 mmol) was added into a stirred solution of tetra-*O*-acetyl-β-[d]{.smallcaps}-glucopyranuronic acid methyl ester (**4**, 6.0 g, 16 mmol) in methanol (200 mL). The solution was refluxed for 6 h and cooled to room temperature. The solution was then concentrated *in vacuo* and the residue was dissolved with CH~2~Cl~2~ (30 mL). The organic layer was washed with water, dried with Na~2~SO~4~ and concentrated *in vacuo* after filtration to give an orange oil of intermediate **5**. Next DBU (0.75 mL, 5 mmol) was added dropwise into a stirred solution of the above product and Cl~3~CCN (8 mL) in CH~2~Cl~2~ at 0 °C. The mixture was stirred for 2 h and concentrated. The residue was purified by column chromatography (petroleum ether--ethyl acetate = 3:1) to give intermediate **6** (3.45 g).

BF~3·~Et~2~O (1.5 mL, 15.3 mmol) was added dropwise into a stirred mixture of WS070117 (3.64 g, 7.50 mmol), intermediate **6** (5.4 g, 11.3 mmol) and 4 Å molecular sieves in CH~2~Cl~2~ (200 mL) at 0 °C. The mixture was stirred for 12 h and neutralized with 2 mL Et~3~N. The solution was concentrated *in vacuo* after filtration and the residue was purified by column chromatography (CH~2~Cl~2~--MeOH = 100:1) to give intermediate **7** (5.2 g, 86.7%). ESI/MS:802.53 \[M + 1\]^+^, ^1^H-NMR (300 MHz, DMSO-*d*~6~, see [Supplementary Materials](#app1-molecules-21-00008){ref-type="app"}) δ: 10.07 (s, 1H), 8.56 (s, 1H), 8.44 (s, 1H), 7.80 (s, 1H), 7.65 (d, *J* = 8.2 Hz, 1H), 7.28 (t, *J* = 8.2 Hz, 1H), 6.71 (d, *J* = 9.8 Hz, 1H), 6.29 (d, *J* = 5.2 Hz, 1H), 6.06 (t, *J* = 5.6 Hz, 1H), 5.66 (dd, *J* = 10.7 Hz, 6.7 Hz, 2H), 5.52 (t, *J* = 9.6 Hz, 1H), 5.09 (m, 2H), 4.71 (d, *J* = 9.9 Hz, 1H), 4.43 (m, 2H), 4.28 (m, 1H), 3.64 (s, 3H), 2.13 (s, 3H), 2.03 (m, 15H).

3.8. Synthesis of N~6~-(3-O-β-[d]{.smallcaps}-Glucuronyphenyl) Adenosine *(**M4**)* {#sec3dot8-molecules-21-00008}
-----------------------------------------------------------------------------------

Cs~2~CO~3~ (2.5 g, 7.7 mmol) was added into a stirred solution of intermediate **7** (4.5 g, 5.6 mmol) in methanol (20 mL). The mixture was stirred at 40 °C for 0.5 h and then cooled to room temperature. The precipitated solid was filtered, redissolved with water (2 mL), and was then cation exchange resin was added to adjust the pH to 6--7. The solution was concentrated *in vacuo* after filtration to give **M4** (2.5 g, 83.3%) as a white solid, $\left\lbrack \mathsf{\alpha} \right\rbrack_{D}^{20}$ = −51.2 (*c* = 0.1, H~2~O), ESI/MS:536.40 \[M + H\]^+^, ^1^H-NMR (400 MHz, methanol-*d*~4~, see [Supplementary Materials](#app1-molecules-21-00008){ref-type="app"}) δ 8.42 (s, 1H), 8.38 (s, 1H), 7.95 (s, 1H), 7.37 (d, *J* = 8.2 Hz, 1H), 7.28 (t, *J* = 8.3 Hz, 1H), 6.84 (d, *J* = 8.2 Hz, 1H), 6.01 (d, *J* = 6.0 Hz, 1H), 5.01 (d, *J* = 6.3 Hz, 1H), 4.77 (t, *J* = 5.7 Hz, 1H), 4.34 (s, 1H), 4.18 (s, 1H), 4.02 (d, *J* = 10.0 Hz, 1H), 3.90 (d, *J* = 12.6 Hz, 1H), 3.76 (d, *J* = 12.5 Hz, 1H), 3.62 (d, *J* = 9.5 Hz, 1H), 3.53 (m, 2H). ^13^C-NMR (100 MHz, methanol-*d*~4~) δ 170.9, 158.0, 152.4, 151.8, 148.6, 140.9, 140.1, 129.1, 120.7, 114.2, 111.5, 108.8, 101.1, 89.8, 86.7, 76.0, 75.3, 74.1, 73.1, 71.7, 71.2, 62.0.

3.9. Synthesis of N~6~-(3-O-β-[d]{.smallcaps}-Glucuronyphenyl) Adenine *(**M2**)* {#sec3dot9-molecules-21-00008}
---------------------------------------------------------------------------------

Concentrated hydrochloric acid (1 mL) was added into a stirred solution of **M4** (1.6 g, 3 mmol) in water (10 mL). The reaction mixture was refluxed for 1 h and then cooled to room temperature. The precipitated solid was filtered and washed with water to give **M2** (0.89 g, 74.1%) as a white solid, $\left\lbrack \mathsf{\alpha} \right\rbrack_{D}^{20}$ = −139.8 (*c* = 0.08, H~2~O), ESI/MS: 404.33 \[M + H\]^+^, ^1^H-NMR (400 MHz, DMSO-*d*~6~, see [Supplementary Materials](#app1-molecules-21-00008){ref-type="app"}) δ 9.95 (brs, 1H), 8.42 (s, 1H), 8.27 (s, 1H), 7.89 (s, 1H), 7.65 (d, *J* = 7.2 Hz, 1H), 7.23 (t, *J* = 8.1 Hz, 1H), 6.70 (d, *J* = 7.9 Hz, 1H), 5.00 (d, *J* = 7.1 Hz, 1H), 3.88 (d, *J* = 9.0 Hz, 1H), 3.34 (m, 3H). ^13^C-NMR (100 MHz, DMSO-*d*~6~) δ 170.6, 157.7, 152.0, 151.5, 141.4, 141.1, 129.6, 114.4, 110.1, 108.7, 100.5, 76.4, 76.1, 73.4, 71.9.

4. Conclusions {#sec4-molecules-21-00008}
==============

Seven metabolites of 2′,3′,5′-tri-*O*-acetyl-*N*~6~-(3-hydroxyphenyl) adenosine (WS070117) were successfully synthesized by deacetylation, hydrolysis, cyclization, sulfonylation and glycosylation reactions. All these compounds were characterized by NMR and HPLC-MS (MS) analyses, and the purities (HPLC) are all higher than 98%, so they could be used as material standards for metabolic research on WS070117.
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